Literature DB >> 19688069

Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma.

Jung Yeon Kim1, Byung-Noe Bae, Kyoung Soo Kim, Eunah Shin, Kyeongmee Park.   

Abstract

PURPOSE: Osteopontin (OPN) binds to CD44 and nuclear factor-kappaB (NFkappaB) and OPN mediates tumorigenesis, invasion and metastasis, but the interrelationships between OPN, CD44 and NFkappaB are not fully understood, and especially in gastric carcinogenesis. We examined the expressions of OPN, CD44, and NFkappaB in untreated gastric adenocarcinomas.
MATERIALS AND METHODS: The materials from 211 cases of gastric adenocarcinoma were immunostained for OPN, CD44 and NFkappaB by using a tissue microarray. The OPN mRNA expression was measured in 10 cases by performing real-time RT-PCR.
RESULTS: The expression of OPN, CD44 and NFkappaB was noted in 61.7%, 11.4% and 26.6% of the adenocarcinoma tissues, respectively. No significant correlation was detected among the expressions of these proteins. The OPN protein expression was negatively correlated with angioinvasion (p<0.05) and patient survival (p<0.05), whereas the CD44 and NFkappaB protein expressions were not correlated with any of the clinicopathological factors we examined. The depth of invasion, lymph node status and perineural invasions were prognostic factors based on the Cox analysis. The OPN mRNA expression showed no significant difference between the adenocarcinoma and the paired normal mucosa on real-time RT-PCR.
CONCLUSION: OPN may have a currently undetermined role in gastric carcinogenesis, and CD44 and NFkappaB may have minor roles in gastric adenocarcinoma.

Entities:  

Keywords:  Adenocarcinoma; CD44; NFκB; Osteopontin; Stomach

Year:  2009        PMID: 19688069      PMCID: PMC2699089          DOI: 10.4143/crt.2009.41.1.29

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  24 in total

1.  Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.

Authors:  Valentina Guarino; Pinuccia Faviana; Giuliana Salvatore; Maria Domenica Castellone; Anna Maria Cirafici; Valentina De Falco; Angela Celetti; Riccardo Giannini; Fulvio Basolo; Rosa Marina Melillo; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

Review 2.  Molecular pathobiology of gastric cancer.

Authors:  W Yasui; K Sentani; J Motoshita; H Nakayama
Journal:  Scand J Surg       Date:  2006       Impact factor: 2.360

3.  Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.

Authors:  Chun-Ying Wu; Ming-Shiang Wu; En-Pei Chiang; Cheng-Chung Wu; Yi-Ju Chen; Chien-Jen Chen; Nai-Hui Chi; Gran-Hum Chen; Jaw-Town Lin
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

4.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

5.  Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue.

Authors:  H Matsuzaki; K Shima; T Muramatsu; Y Ro; S Hashimoto; T Shibahara; M Shimono
Journal:  J Oral Pathol Med       Date:  2007-01       Impact factor: 4.253

6.  Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells.

Authors:  S Philip; A Bulbule; G C Kundu
Journal:  J Biol Chem       Date:  2001-09-19       Impact factor: 5.157

7.  Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.

Authors:  Jia-Lin Lee; Mei-Jung Wang; Putty-Reddy Sudhir; Gen-Der Chen; Chin-Wen Chi; Jeou-Yuan Chen
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

8.  Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.

Authors:  Lilly Y W Bourguignon; Weiliang Xia; Gabriel Wong
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

9.  Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.

Authors:  Stephen M Selkirk; Jay Morrow; Tara A Barone; Alan Hoffer; Jeffrey Lock; Anne DeChant; Saisho Mangla; Robert J Plunkett; Robert H Miller
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

10.  Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.

Authors:  Rajeev S Samant; David W Clark; Rebecca A Fillmore; Muzaffer Cicek; Brandon J Metge; Kondethimmana H Chandramouli; Ann F Chambers; Graham Casey; Danny R Welch; Lalita A Shevde
Journal:  Mol Cancer       Date:  2007-01-16       Impact factor: 27.401

View more
  11 in total

1.  CD44 family proteins in gastric cancer: a meta-analysis and narrative review.

Authors:  Ying Wu; Zhi Li; Chenlu Zhang; Kai Yu; Zan Teng; Guoliang Zheng; Shuang Wang; Yunpeng Liu; Lei Cui; Xiaosong Yu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma.

Authors:  Sadhna Dhingra; Wei Feng; Robert E Brown; Zhongren Zhou; Thaer Khoury; Rongzhen Zhang; Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

Review 3.  Gastric cancer stem cells: evidence, potential markers, and clinical implications.

Authors:  Daniel Brungs; Morteza Aghmesheh; Kara L Vine; Therese M Becker; Martin G Carolan; Marie Ranson
Journal:  J Gastroenterol       Date:  2015-10-01       Impact factor: 7.527

4.  Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Authors:  Akio Shiomi; Masatoshi Kusuhara; Takashi Sugino; Teiichi Sugiura; Keiichi Ohshima; Takeshi Nagashima; Kenichi Urakami; Masakuni Serizawa; Hideyuki Saya; Ken Yamaguchi
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

5.  Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma.

Authors:  Anahita Nosrati; Farshad Naghshvar; Somaieh Khanari
Journal:  Int J Mol Cell Med       Date:  2014

Review 6.  Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Tingting Sun; Peng Li; Diwen Sun; Qingao Bu; Guoqiang Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis.

Authors:  Mingfei Zhao; Feng Liang; Buyi Zhang; Wei Yan; Jianmin Zhang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

Review 8.  Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.

Authors:  Li Lu; Menglin Wu; Longhao Sun; Weidong Li; Weihua Fu; Xuening Zhang; Tong Liu
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 9.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

10.  Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.

Authors:  Xiaobin Gu; Xian-Shu Gao; Mingwei Ma; Shangbin Qin; Xin Qi; Xiaoying Li; Shaoqian Sun; Hao Yu; Wen Wang; Dong Zhou
Journal:  Oncotarget       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.